logo
Digital Dementia is a real thing, and can literally 'fry' your brain: here's why you should be worried

Digital Dementia is a real thing, and can literally 'fry' your brain: here's why you should be worried

Time of India23-04-2025

There is no escaping technology in today's digital age. You name it and we have it - tabs, smart phones, laptops etc. These devices, though convenient, have made it difficult for us to ever be disconnected - both from people and the world around us. While there is no denying that there is a certain level of dependability on these devices, an excessive use of them can literally 'fry' your brain, known as
Digital Dementia
. Let's learn more about it, and figure out a way to escape from its trap...
What is Digital Dementia?
Digital dementia is a term first coined by German neuroscientist Manfred Spitzer in 2012. It refers to a decline in brain function caused by over dependence on digital devices. When we depend too much on technology to remember things or solve problems, our brain's natural ability to do these tasks weakens over time. This leads to difficulties with memory, attention, and decision-making.
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Warehouse Temperature and Humidity Monitoring: Key to Efficient Operations
Temperature Monitoring
Undo
What are the symptoms of Digital Dementia?
The signs of digital dementia could be varied, but can include:
Trouble remembering events (even recent ones) and other information
Difficulty focusing or maintaining attention
Struggling to find the right words when speaking
Poor problem-solving skills
Displaying no empathy/social skills
Emotional difficulties
Why does it occur?
There are several reasons digital dementia develops:
No brain exercise:
We rely on phones and computers to store information like phone numbers or appointments. This means our brain practices remembering less, causing memory skills to weaken over time.
Constant distractions:
Notifications and multitasking on devices shorten our attention span and make it hard to focus on one task for long.
Less physical activity:
Spending too much time sitting and using screens lowers blood flow to the brain, which is important for
brain health
.
Less in person interaction: Digital communication can reduce real social contact, affecting emotional understanding and social skills.
The impact it has
Digital dementia doesn't just affect our memory; it in fact changes how we think, feel, and interact with others. Poor concentration and forgetfulness can even hamper our performance at work, while reduced empathy and social skills may lead to loneliness or misunderstandings. Over time, these changes can lower quality of life and mental well-being.
How to protect yourself from this condition
Limit screen time:
Try to reduce recreational screen use, especially for children, to less than two hours a day.
Stay physically active: Exercise improves blood flow to the brain and supports memory and thinking skills, all while you stay away from your phone for the hour/s you are exercising!
Reduce technology use (as much as you can):
Focus on one task at a time and avoid constant multitasking or checking notifications.
Engage your brain:
Read books, solve puzzles, learn new skills, or play musical instruments to keep your brain active.
Get quality sleep: Avoid screens at least an hour before bedtime to improve sleep, which is vital for brain health.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy
Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy

Time of India

time11 hours ago

  • Time of India

Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda. The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term focus on experimental cancer treatments and show that its success as Pfizer 's COVID-19 vaccine partner was not a one-off achievement. It also underscores a push across the pharma sector to master a new dual mechanism of action in oncology that activates the immune system - similar to an established drug class including Merck & Co's Keytruda - but which also cuts a tumour's blood supply. BioNTech's German-listed shares surged 16.7% by 1236 GMT to a six-week high. The two companies said in separate statements that the U.S. group will co-develop and co-commercialize BioNTech's drug, BNT327, for multiple solid tumour types. Live Events BioNTech's CEO and co-founder Ugur Sahin said the collaboration will serve "to accelerate and broadly expand BNT327's development to fully realize its potential." The companies said in presentation slides that Bristol Myers was bringing global networks in clinical development and manufacturing to the partnership, among other benefits. BioNTech said in a statement that the partners were seeking to set a new standard of care in the cancer market segment, now dominated by so-called checkpoint inhibitors including Keytruda with $29.5 billion in 2024 sales. Western drugmakers have struck a host of deals to win access to the new drug technology, known as PD-1/VEGF bispecific antibodies, which was pioneered in China. Pfizer last month partnered with China's 3SBio , paying $1.25 billion upfront and up to another $4.8 billion depending on developmental achievements. Merck & Co, whose Keytruda business is under threat from the sector's development push, in November last year licensed an early-stage cancer drug from China-based LaNova Medicines for up to $3.3 billion. "We are now starting to see an industry vote of confidence in the differentiation of this novel mechanism," BMO Capital Markets analysts said in a note. They welcomed BioNTech "partnering with a big pharma name to help manage a broad development plan and potential commercialization". Shares in Instil Bio, which is working with China's ImmuneOnco on a similar compound, soared 24% in U.S. trade on Monday. Summit Therapeutics and China's Akeso have formed another partnership in the development race with a drug candidate called ivonescimab. BioNTech took full ownership of BNT327 through the acquisition of China's Biotheus earlier this year for $800 million upfront and up to $150 million contingent on development achievements. It previously held certain rights in the drug under a 2023 collaboration deal. In addition to an initial payment of $1.5 billion, Bristol plans to pay BioNTech $2 billion in non-contingent anniversary payments through 2028. BioNTech may also earn up to $7.6 billion in development, regulatory and commercial milestones, Bristol said. The companies will share global profits and losses from the drug equally, and joint development and manufacturing costs will also be shared on a 50/50 basis, with some exceptions. BNT327 is being tested as a first-line treatment in extensive stage small cell lung cancer and non-small cell lung cancer. More than 1,000 patients have been treated with the drug to date. Economic Times WhatsApp channel )

3 patients killed in fire that broke out at a hospital in German city of Hamburg
3 patients killed in fire that broke out at a hospital in German city of Hamburg

Time of India

time2 days ago

  • Time of India

3 patients killed in fire that broke out at a hospital in German city of Hamburg

Firefighters with breathing apparatus and a ladder truck work at the Marienkrankenhaus hospital in Hamburg, Germany (AP) BERELIN: Three patients were killed and many people were injured, one of them critically, in a fire that broke out overnight at a hospital in the German city of Hamburg, authorities said on Sunday. Firefighters were alerted to the blaze at the hospital, the Marienkrankenhaus, shortly after midnight. It broke out in a room in the geriatric ward, on the ground floor of the building, and spread to the facade of the floor above. Smoke spread across the building's four floors. It wasn't immediately clear what caused the fire. The fire department said that three adult patients were killed and more than 30 people injured, the German news agency dpa reported. Of those, one was in life-threatening condition, 18 had serious injuries and 15 were slightly hurt. Authorities initially gave a higher figure for light injuries and said two people were critically hurt. A section of the hospital had to be evacuated. Injured patients were treated mostly at the hospital itself, though two were taken to nearby clinics. The fire was extinguished within about 20 minutes. Firefighters said they found several patients at the windows calling for help. People were rescued using ladders and through the building itself.

3 dead, dozens injured in hospital fire in Hamburg, Germany
3 dead, dozens injured in hospital fire in Hamburg, Germany

United News of India

time2 days ago

  • United News of India

3 dead, dozens injured in hospital fire in Hamburg, Germany

Berlin, June 1 (UNI) A fire broke out overnight at a hospital in the Hohenfelde district of the northern German city of Hamburg, killing three patients and injuring more than 50 others, local authorities confirmed on Sunday. According to the Hamburg fire department, two of the injured are in life-threatening condition, while 16 others sustained serious injuries and 36 suffered minor injuries. The fire started in the geriatric ward on the first floor of the hospital and spread to the second floor. Firefighters were alerted to the fire shortly after midnight. Thick smoke from the fire spread throughout every floor of the building, prompting a large-scale emergency response. Firefighters conducted rescues through open windows, and the fire was completely extinguished in the early hours of Sunday. The cause of the fire remains under investigation. UNI XINHUA ARN

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store